<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170935</url>
  </required_header>
  <id_info>
    <org_study_id>1160.30</org_study_id>
    <nct_id>NCT02170935</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery</brief_title>
  <official_title>Multicenter, Open-label-study to Assess PK Profile of a Single Oral Dose of 150 mg BIBR 1048 (Capsule) in Patients Shortly After Primary Elective Total Hip Replacement Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3
      hours post surgery in hip replacement patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to maximum plasma concentration (Tmax)</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total clearance of drug from plasma</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>terminal elimination constant</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time of last measureable BIBR 953 ZW plasma concentration (Tf)</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration time curve until Tf (AUC0-Tf)</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration time extrapolated to infinity (AUC0-infinity)</measure>
    <time_frame>pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 capsule</intervention_name>
    <arm_group_label>BIBR 1048 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo a primary elective total hip replacement

          -  Male or female being 18 years or older (women of child bearing potential may not be
             included)

          -  Patients weighing at least 40 kg

          -  Written informed consent for participation

        Exclusion Criteria:

          -  Bleeding disorders, e.g. history of intracranial, intraocular, gastrointestinal or
             pulmonary bleeding, known thrombocytopenia, history of haemorrhagic stroke

          -  Known renal disease

          -  Known liver disease, alcohol or drug misuse

          -  Known malignancy

          -  Treatment with another study drug in the past month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

